文献速递头颈部肿瘤放疗放疗物理与技术

口咽癌放疗处方剂量全球差异:70 Gy何时真正等同70 Gy?

Global Dose Prescription Variances Exemplified Through Oropharynx Cancer: When Is 70 Gray 70 Gray?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-01-31

该研究纳入8个国际中心2017年起连续收治的1514例口咽癌调强放疗或容积旋转调强放疗患者,发现40种不同处方剂量,范围从55 Gy/20次至70 Gy/35次。归一化至70 Gy处方后,各中心临床靶区平均剂量中位差异为4%,近最小靶区剂量D98%范围为68.7至71.4 Gy。研究提示头颈癌处方剂量实施缺乏全球标准化,影响患者照护、协作研究及降剂量或剂量绘画策略。

要点

  • 8个国际中心1514例口咽癌患者共出现40种不同处方剂量。
  • 处方剂量范围从55 Gy/20次至70 Gy/35次不等。
  • 归一至70 Gy后临床靶区平均剂量中位差异为4%,D98%为68.7至71.4 Gy。

核心结论

  • 头颈癌处方剂量在全球范围内实施差异广泛,缺乏标准化方法,可能影响患者照护、协作研究及降剂量或剂量绘画策略。

研究设计与样本

  • 研究纳入2017年起在8个国际知名放疗科连续接受调强放疗或容积旋转调强放疗的口咽癌患者,中心分为北美、北欧、大洋洲和亚洲4类。

主要发现

  • 共纳入1514例患者,出现40种不同处方剂量,范围从55 Gy/20次至70 Gy/35次。
  • 归一化至70 Gy处方后,各中心临床靶区平均剂量中位差异为4%。
  • 欧洲和大洋洲中心偏差为0.4%,北美和亚洲中心变异为2%。
  • 近最小临床靶区剂量D98%范围为68.7至71.4 Gy。

临床怎么用

  • 解读国际多中心放疗结局时需注意各中心处方剂量实施差异,避免直接比较名义剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: Radiation therapy treatment planning hinges on a critical factor: the prescribed dose. Surprisingly, there is no consistent, standardized global approach to evaluating the dosimetry of this prescription across different centers treating head and neck cancer (HNC). This study aimed to quantify global dose variations for identical prescriptions across international centers treating oropharyngeal cancer, to establish the foundation for future outcome-based studies and improve consistency of interpretation worldwide. MATERIALS AND METHODS: The study included patients with oropharyngeal cancer who were consecutively treated from 2017 onward with intensity-modulated radiation therapy or volumetric modulated arc therapy at 8 globally recognized radiation therapy departments. These centers were categorized into 4 categories: North American, North European, Oceanic, and Asian. RESULTS: The study included 1514 patients from 8 centers and revealed 40 different dose prescriptions, ranging from 55 Gy in 20 to 70 Gy in 35 fractions. When normalized to a 70 Gy prescription, the mean clinical target volume dose showed a 4% median difference across centers. European and Oceania centers deviated by 0.4%, whereas North American and Asian centers had 2% variability. Near-minimum clinical target volume doses (D98%) ranged from 68.7 to 71.4 Gy. CONCLUSIONS: The study underscores the wide-ranging implementation of dose prescriptions in HNC. The lack of a standardized global approach to HNC treatment dose prescription carries potential implications for patient care, collaborative research, and treatment de-escalation or radiation therapy dose-painting strategies. This study highlights the need for careful interpretation of dose prescription standards across international centers, to analyze radiation therapy outcomes more accurately in light of their varied implementation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hansen CR, Tadic T, Sharma M, et al. Global Dose Prescription Variances Exemplified Through Oropharynx Cancer: When Is 70 Gray 70 Gray? Int J Radiat Oncol Biol Phys. 2026. PMID: 41628865. doi:10.1016/j.ijrobp.2026.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。